Skip to main content
. 2021 Jul 25;13(15):3737. doi: 10.3390/cancers13153737

Figure 1.

Figure 1

Thymoquinone targets SUCLA2 loss that collaterally takes place with RB1 homozygous or heterozygous deletion.